Cover
Cover - USD ($) | 12 Months Ended | ||
Apr. 30, 2023 | Jun. 09, 2023 | Oct. 31, 2022 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Apr. 30, 2023 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Current Fiscal Year End Date | --04-30 | ||
Entity File Number | 001-32839 | ||
Entity Registrant Name | AVID BIOSERVICES, INC. | ||
Entity Central Index Key | 0000704562 | ||
Entity Tax Identification Number | 95-3698422 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Address, Address Line One | 14191 Myford Road | ||
Entity Address, City or Town | Tustin | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 92780 | ||
City Area Code | (714) | ||
Local Phone Number | 508-6100 | ||
Title of 12(b) Security | Common Stock, $0.001 par value per share | ||
Trading Symbol | CDMO | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 887,300,000 | ||
Entity Common Stock, Shares Outstanding | 62,729,154 | ||
ICFR Auditor Attestation Flag | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
Auditor Firm ID | 42 | ||
Auditor Name | Ernst & Young LLP | ||
Auditor Location | Irvine, California |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Apr. 30, 2023 | Apr. 30, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 38,542 | $ 126,166 |
Accounts receivable, net | 18,298 | 20,547 |
Contract assets | 9,609 | 5,369 |
Inventory | 43,908 | 26,062 |
Prepaid expenses and other current assets | 2,094 | 1,879 |
Total current assets | 112,451 | 180,023 |
Property and equipment, net | 177,369 | 92,955 |
Operating lease right-of-use assets | 42,772 | 36,806 |
Deferred tax assets | 113,639 | 115,082 |
Other assets | 4,473 | 4,627 |
Restricted cash | 350 | 350 |
Total assets | 451,054 | 429,843 |
Current liabilities: | ||
Accounts payable | 24,593 | 9,504 |
Accrued compensation and benefits | 8,780 | 8,418 |
Contract liabilities | 37,352 | 53,798 |
Current portion of operating lease liabilities | 1,358 | 2,969 |
Other current liabilities | 1,626 | 1,072 |
Total current liabilities | 73,709 | 75,761 |
Convertible senior notes, net | 140,623 | 139,577 |
Operating lease liabilities, less current portion | 45,690 | 37,886 |
Finance lease liabilities, less current portion | 1,562 | 2,093 |
Total liabilities | 261,584 | 255,317 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates | 0 | 0 |
Common stock, $0.001 par value; 150,000 shares authorized; 62,692 and 61,807 shares issued and outstanding at respective dates | 63 | 62 |
Additional paid-in capital | 620,224 | 605,841 |
Accumulated deficit | (430,817) | (431,377) |
Total stockholders’ equity | 189,470 | 174,526 |
Total liabilities and stockholders’ equity | $ 451,054 | $ 429,843 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands | Apr. 30, 2023 | Apr. 30, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000 | 5,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 150,000 | 150,000 |
Common stock, shares issued | 62,692 | 61,807 |
Common stock, shares outstanding | 62,692 | 61,807 |
CONSOLIDATED STATEMENTS OF INCO
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Income Statement [Abstract] | |||
Revenues | $ 149,266 | $ 119,597 | $ 95,868 |
Cost of revenues | 117,786 | 82,949 | 66,561 |
Gross profit | 31,480 | 36,648 | 29,307 |
Operating expenses: | |||
Selling, general and administrative | 27,879 | 21,226 | 17,064 |
Total operating expenses | 27,879 | 21,226 | 17,064 |
Operating income | 3,601 | 15,422 | 12,243 |
Interest expense | (2,600) | (2,680) | (1,164) |
Other income (expense), net | 1,002 | (81) | 133 |
Net income before income taxes | 2,003 | 12,661 | 11,212 |
Income tax (expense) benefit | (1,443) | 115,011 | 0 |
Net income | 560 | 127,672 | 11,212 |
Comprehensive income | 560 | 127,672 | 11,212 |
Series E preferred stock accumulated dividends | 0 | 0 | (4,455) |
Impact of Series E preferred stock redemption | 0 | 0 | (3,439) |
Net income attributable to common stockholders | $ 560 | $ 127,672 | $ 3,318 |
Net income per share attributable to common stockholders: | |||
Basic | $ 0.01 | $ 2.08 | $ 0.06 |
Diluted | $ 0.01 | $ 1.84 | $ 0.06 |
Weighted average common shares outstanding: | |||
Basic | 62,268 | 61,484 | 58,222 |
Diluted | 63,782 | 70,474 | 59,426 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Preferred Stock [Member] | |||
Statement [Line Items] | |||
Beginning balance, value | $ 2 | ||
Beginning balance, shares | 1,648 | ||
Cumulative-effect adjustment from modified retrospective adoption of ASU 2020-06 | |||
Series E preferred stock dividends paid ($2.705 per share) | |||
Conversion of Series E preferred stock to common stock | |||
Conversion of Series E preferred stock to common stock, shares | (28) | ||
Redemption of Series E preferred stock | $ (2) | ||
Redemption of Series E preferred stock, shares | (1,620) | ||
Common stock issued, net of issuance costs of $2,359 | |||
Common stock issued under equity compensation plans | |||
Equity component of convertible senior notes | |||
Purchase of capped calls related to convertible senior notes | |||
Stock-based compensation expense | |||
Net income | |||
Ending balance, value | |||
Ending balance, shares | |||
Common Stock [Member] | |||
Statement [Line Items] | |||
Beginning balance, value | $ 62 | $ 61 | $ 56 |
Beginning balance, shares | 61,807 | 61,069 | 56,483 |
Cumulative-effect adjustment from modified retrospective adoption of ASU 2020-06 | |||
Series E preferred stock dividends paid ($2.705 per share) | |||
Conversion of Series E preferred stock to common stock | |||
Conversion of Series E preferred stock to common stock, shares | 34 | ||
Redemption of Series E preferred stock | |||
Common stock issued, net of issuance costs of $2,359 | $ 4 | ||
Common stock issued, net of issuance costs of $2,359, shares | 3,833 | ||
Common stock issued under equity compensation plans | $ 1 | $ 1 | $ 1 |
Common stock issued under equity compensation plans, shares | 885 | 738 | 719 |
Equity component of convertible senior notes | |||
Purchase of capped calls related to convertible senior notes | |||
Stock-based compensation expense | |||
Net income | |||
Ending balance, value | $ 63 | $ 62 | $ 61 |
Ending balance, shares | 62,692 | 61,807 | 61,069 |
Additional Paid-in Capital [Member] | |||
Statement [Line Items] | |||
Beginning balance, value | $ 605,841 | $ 637,534 | $ 612,909 |
Cumulative-effect adjustment from modified retrospective adoption of ASU 2020-06 | (42,431) | ||
Series E preferred stock dividends paid ($2.705 per share) | $ (4,455) | ||
Conversion of Series E preferred stock to common stock | |||
Redemption of Series E preferred stock | $ (40,488) | ||
Common stock issued, net of issuance costs of $2,359 | 32,137 | ||
Common stock issued under equity compensation plans | 3,405 | 3,358 | 3,983 |
Equity component of convertible senior notes | 42,431 | ||
Purchase of capped calls related to convertible senior notes | (12,837) | ||
Stock-based compensation expense | 10,978 | 7,380 | 3,854 |
Net income | |||
Ending balance, value | 620,224 | 605,841 | 637,534 |
Retained Earnings [Member] | |||
Statement [Line Items] | |||
Beginning balance, value | (431,377) | (559,859) | (571,071) |
Cumulative-effect adjustment from modified retrospective adoption of ASU 2020-06 | 810 | ||
Series E preferred stock dividends paid ($2.705 per share) | |||
Conversion of Series E preferred stock to common stock | |||
Redemption of Series E preferred stock | |||
Common stock issued, net of issuance costs of $2,359 | |||
Common stock issued under equity compensation plans | |||
Equity component of convertible senior notes | |||
Purchase of capped calls related to convertible senior notes | |||
Stock-based compensation expense | |||
Net income | 560 | 127,672 | 11,212 |
Ending balance, value | (430,817) | (431,377) | (559,859) |
Beginning balance, value | 174,526 | 77,736 | 41,896 |
Cumulative-effect adjustment from modified retrospective adoption of ASU 2020-06 | (41,621) | ||
Series E preferred stock dividends paid ($2.705 per share) | $ (4,455) | ||
Conversion of Series E preferred stock to common stock | |||
Redemption of Series E preferred stock | $ (40,490) | ||
Common stock issued, net of issuance costs of $2,359 | 32,141 | ||
Common stock issued under equity compensation plans | 3,406 | 3,359 | 3,984 |
Equity component of convertible senior notes | 42,431 | ||
Purchase of capped calls related to convertible senior notes | (12,837) | ||
Stock-based compensation expense | 10,978 | 7,380 | 3,854 |
Net income | 560 | 127,672 | 11,212 |
Ending balance, value | $ 189,470 | $ 174,526 | $ 77,736 |
CONSOLIDATED STATEMENTS OF ST_2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands | 12 Months Ended |
Apr. 30, 2021 USD ($) $ / shares | |
Statement of Stockholders' Equity [Abstract] | |
Preferred Stock, Dividends, Per Share, Cash Paid | $ / shares | $ 2.705 |
Payment of stock issuance costs | $ | $ 2,359 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net income | $ 560 | $ 127,672 | $ 11,212 |
Adjustments to reconcile net income to net cash (used in) provided by operating activities: | |||
Stock-based compensation | 10,978 | 7,380 | 3,854 |
Depreciation and amortization | 7,210 | 4,480 | 3,453 |
Amortization of debt discount and issuance costs | 1,046 | 1,030 | 916 |
Deferred income taxes | 1,443 | (115,082) | 0 |
Loss on disposal and/or impairment of property and equipment | 139 | 381 | 0 |
Changes in operating assets and liabilities: | |||
Accounts receivable, net | 2,249 | (1,705) | (10,236) |
Contract assets | (4,240) | 743 | (2,812) |
Inventory | (17,846) | (14,191) | (988) |
Prepaid expenses and other assets | (61) | (4,232) | (1,260) |
Accounts payable | 964 | (943) | (608) |
Accrued compensation and benefits | 362 | (376) | 5,775 |
Contract liabilities | (16,446) | 3,029 | 21,649 |
Other accrued expenses and liabilities | 755 | 1,279 | 227 |
Net cash (used in) provided by operating activities | (12,887) | 9,465 | 31,182 |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||
Purchase of property and equipment | (77,638) | (56,411) | (9,864) |
Net cash used in investing activities | (77,638) | (56,411) | (9,864) |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Proceeds from issuance of common stock under equity compensation plans | 3,406 | 3,359 | 3,984 |
Proceeds from issuance of common stock, net of issuance costs | 0 | 0 | 32,141 |
Proceeds from issuance of convertible senior notes, net of issuance costs | 0 | 0 | 138,464 |
Purchases of capped calls related to convertible senior notes | 0 | 0 | (12,837) |
Repayment of note payable | 0 | 0 | (4,379) |
Dividends paid on preferred stock | 0 | 0 | (4,455) |
Redemption of preferred stock | 0 | 0 | (37,051) |
Impact of preferred stock redemption | 0 | 0 | (3,439) |
Principal payments on finance leases | (505) | (162) | (93) |
Net cash provided by financing activities | 2,901 | 3,197 | 112,335 |
Net (decrease) increase in cash, cash equivalents and restricted cash | (87,624) | (43,749) | 133,653 |
Cash, cash equivalents and restricted cash, beginning of period | 126,516 | 170,265 | 36,612 |
Cash, cash equivalents and restricted cash, end of period | 38,892 | 126,516 | 170,265 |
Supplemental disclosures of cash flow information: | |||
Cash paid for interest | 1,118 | 1,670 | 5 |
Cash paid for income taxes | 260 | 64 | 0 |
Supplemental disclosures of non-cash activities: | |||
Unpaid purchases of property and equipment in accounts payable | $ 14,125 | $ 1,190 | $ 3,939 |
Description of Company and Basi
Description of Company and Basis of Presentation | 12 Months Ended |
Apr. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Description of Company and Basis of Presentation | Note 1 – Description of Company and Basis of Presentation We are a dedicated contract development and manufacturing organization (“CDMO”) that provides a comprehensive range of services from process development to Current Good Manufacturing Practices (“CGMP”) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. Except where specifically noted or the context otherwise requires, references to “Avid,” the “Company,” “we,” “us,” and “our,” in this Annual Report refer to Avid Bioservices, Inc. and its subsidiary. Basis of Presentation and Preparation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include our accounts and those of our subsidiary. All intercompany accounts and transactions among the consolidated entities have been eliminated in the consolidated financial statements. The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the consolidated financial statements and on various other assumptions that are believed to be reasonable under the circumstances. Accounting estimates and judgments are inherently uncertain and actual results could differ materially from these estimates. Segment Reporting Our business operates in one operating segment, our contract manufacturing and development services segment. Accordingly, we reported our financial results for one reportable segment |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Apr. 30, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2 – Summary of Significant Accounting Policies Cash and Cash Equivalents We consider all short-term investments readily convertible to cash, without notice or penalty, with an initial maturity of 90 days or less to be cash equivalents. Restricted Cash Under the terms of an operating lease related to one of our facilities (Note 4), we are required to maintain a letter of credit as collateral. Accordingly, at April 30, 2023 and 2022, restricted cash of $ 0.4 million The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Schedule of restricted cash As of April 30, 2023 2022 2021 Cash and cash equivalents $ 38,542 $ 126,166 $ 169,915 Restricted cash 350 350 350 Total cash, cash equivalents and restricted cash $ 38,892 $ 126,516 $ 170,265 Revenue Recognition We recognize revenue in accordance with the authoritative guidance of ASC 606, Revenue from Contracts with Customers Revenue recognized from services provided under our customer contracts is disaggregated into manufacturing and process development revenue streams. Manufacturing revenue Manufacturing revenue generally represents revenue from the manufacturing of customer products recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a manufacturing contract, a quantity of manufacturing runs are ordered at a specified scale with prescribed delivery dates, where the product is manufactured according to the customer’s specifications and typically includes only one performance obligation. Each manufacturing run represents a distinct service that is sold separately and has stand-alone value to the customer. The products are manufactured exclusively for a specific customer and have no alternative use. The customer retains control of its product during the entire manufacturing process and can make changes to the process or specifications at its request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. Process development revenue Process development revenue generally represents revenue from services associated with the custom development of a manufacturing process and analytical methods for a customer’s product. Process development revenue is recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a process development contract, the customer owns the product details and process, which has no alternative use. These process development projects are customized to each customer to meet its specifications and typically includes only one performance obligation. Each process represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by our services and can make changes to its process or specifications upon request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. The following table summarizes our manufacturing and process development revenue streams (in thousands): Disaggregation of revenue Fiscal Year Ended April 30, 2023 2022 2021 Manufacturing revenues $ 125,416 $ 99,282 $ 83,678 Process development revenues 23,850 20,315 12,190 Total revenues $ 149,266 $ 119,597 $ 95,868 The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets (unbilled receivables), and contract liabilities (customer deposits and deferred revenue). Contract assets are recorded when our right to consideration is conditioned on something other than the passage of time. Contract assets are reclassified to accounts receivable on the consolidated balance sheet when our rights become unconditional. Contract liabilities represent customer deposits and deferred revenue billed and/or received in advance of our fulfillment of performance obligations. Contract liabilities convert to revenue as we perform our obligations under the contract. During the fiscal years ended April 30, 2023 and 2022, we recognized revenue of $ 40.8 million 34 The transaction price for services provided under our customer contracts reflects our best estimates of the amount of consideration to which we are entitled in exchange for providing goods and services to our customers. For contracts with multiple performance obligations, we allocate transaction price to each performance obligation identified in a contract on a relative standalone selling price basis. We generally determine relative standalone selling prices based on the price observed in the customer contract for each distinct performance obligation. If observable standalone selling prices are not available, we may estimate the applicable standalone selling price based on the pricing of other comparable services or on a price that we believe the market is willing to pay for the applicable service. In determining the transaction price, we also considered the different sources of variable consideration including, but not limited to, discounts, credits, refunds, price concessions or other similar items. We have included in the transaction price some or all of an amount of variable consideration, utilizing the most likely method, only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The actual amount of consideration ultimately received may differ. In addition, our customer contracts generally include provisions entitling us to a cancellation or postponement fee when a customer cancels or postpones its commitments prior to our initiation of services, therefore not utilizing their reserved capacity. The determination of such cancellation and postponement fees are based on the terms stated in the related customer contract but are generally considered substantive for accounting purposes and create an enforceable right and obligation due to us when the cancellation or postponement occurs. Accordingly, we recognize such fees, subject to variable consideration, as revenue upon the cancellation or postponement date utilizing the most likely method. Management may be required to exercise judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations, estimating variable consideration, and estimating the progress towards the satisfaction of performance obligations. If actual results in the future vary from our estimates, the estimates will be adjusted, which will affect revenues in the period that such variances become known. During the fiscal year ended April 30, 2023, we recognized revenue of $ 3.0 million 14.7 million We apply the practical expedient available under ASC 606 that permits us not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. As of April 30, 2023, we do not have any unsatisfied performance obligations for contracts greater than one year. Costs incurred to obtain a contract are not material. These costs are generally employee sales commissions, which are expensed as incurred and included in selling, general and administrative expense in the consolidated statements of income and comprehensive income. Accounts Receivable, Net Accounts receivable is primarily comprised of amounts owed to us for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for doubtful accounts, if necessary. We apply judgment in assessing the ultimate realization of our receivables and we estimate an allowance for doubtful accounts based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. Based on our analysis of our accounts receivable balance as of April 30, 2023, we determined an allowance for doubtful accounts of $ 0.5 million Based on our analysis of our accounts receivable balance as of April 30, 2022, we determined an allowance for doubtful accounts of $ 18.4 million Concentrations of Credit Risk and Customer Base Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents, accounts receivable, net and contract assets. As of April 30, 2023 and 2022, we maintain our cash balances primarily with a major commercial bank and our deposits held with the bank exceed the amount of government insurance limits provided on our deposits. We are exposed to credit risk in the event of default by the major commercial bank holding our cash balances to the extent of the cash amounts recorded on the accompanying consolidated balance sheets exceed the amount of government insurance limits provided on our deposits. Our accounts receivable from amounts billed for services provided under customer contracts are derived from a limited number of customers. Most customer contracts require up-front payments and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs. At April 30, 2023 and 2022, approximately 76% and 84%, respectively, of our accounts receivable, net were due from our top ten customers. Our revenues are derived from a limited number of customers. Historically, these customers have not entered into long-term contracts because their need for drug supply depends on a variety of factors, including a product’s stage of development, the timing of regulatory filings and approvals, the product needs of their collaborators, if applicable, their financial resources and the market demand with respect to a commercial product. The table below identifies each of our customers that accounted for 10% or more of our total revenues during any of the fiscal years ended April 30, 2023, 2022 and 2021: Concentration of revenues Customer Geographic Location 2023 2022 2021 Halozyme Therapeutics, Inc. (1) U.S. 53 % 41 % 51 % IGM Biosciences, Inc. U.S. * 11 * Gilead Sciences, Inc. U.S. – * 16 ______________ (1) Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates. * Represents a percentage less than 10% of our total revenues. We attribute revenue to the individual countries where the customer is headquartered. Approximately 100 Leases We account for our leases in accordance with the authoritative guidance of ASC 842, Leases Our operating leases may include options to extend the lease which are included in the lease term when it is reasonably certain that we will exercise a renewal option. Operating lease expense is recognized on a straight-line basis over the expected lease term. Our finance lease with a term greater than one year is included as an asset within property and equipment, net and a lease liability equal to the present value of the minimum lease payments is included in other current liabilities and finance lease liabilities, less current portion in our consolidated balance sheets. The present value of the finance lease payments is calculated using the implicit interest rate in the lease. Finance lease ROU assets are amortized on a straight-line basis over the expected useful life of the asset and the carrying amount of the lease liability is adjusted to reflect interest, which is recorded as interest expense. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets and lease expense for these short-term leases is recognized on a straight-line basis over the lease term. We have also elected the practical expedient to not separate lease components from non-lease components. Inventory Inventory consists of raw materials inventory and is valued at the lower of cost, determined by the first-in, first-out method, or net realizable value. We periodically review raw materials inventory for potential impairment and adjust inventory to its net realizable value based on the estimate of future use and reduce the carrying value of inventory as deemed necessary. Property and Equipment Property and equipment is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related asset, which are generally as follows: Schedule of estimated useful lives of property Description Estimated Useful Life Leasehold improvements Shorter of estimated useful life or lease term Laboratory and manufacturing equipment 5 – 15 years Computer equipment and software 3 – 5 years Furniture, fixtures and office equipment 5 – 10 years Costs for property and equipment not yet placed into service have been capitalized as construction-in-progress. These costs are primarily related to equipment and leasehold improvements associated with our manufacturing facilities, and will be depreciated in accordance with the above guidelines once placed into service. Interest costs incurred during construction of major capital projects are capitalized as construction-in-progress until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Interest capitalized as construction-in-progress for the fiscal years ended April 30, 2023 and 2022, was $ 0.4 million 0.2 million Schedule of property and equipment April 30, 2023 2022 Leasehold improvements $ 97,514 $ 37,345 Laboratory and manufacturing equipment 35,501 30,089 Computer equipment and software 5,028 5,326 Furniture, fixtures and office equipment 1,681 843 Construction-in-progress 68,013 43,809 Total property and equipment, gross 207,737 117,412 Less: accumulated depreciation and amortization (30,368 ) (24,457 ) Total property and equipment, net $ 177,369 $ 92,955 Depreciation and amortization expense for the fiscal years ended April 30, 2023, 2022 and 2021 was $ 7.2 million 4.5 million 3.5 million Capitalized Software Implementation Cost We capitalize certain implementation costs incurred under cloud computing hosting arrangements. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within other assets on the accompanying consolidated balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Impairment Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. If such events or changes in circumstances arise, we compare the carrying amount of the long-lived assets to the estimated future undiscounted cash flows expected to be generated by the long-lived assets. If the long-lived assets are determined to be impaired, any excess of the carrying value of the long-lived assets over its estimated fair value is recognized as an impairment loss. For the fiscal year ended April 30, 2023, there were indicators of impairment of the value of certain long-lived assets that resulted in an impairment loss of $ 0.1 million no Fair Value of Financial Instruments The carrying amounts in the accompanying consolidated balance sheets for cash and cash equivalents, restricted cash, accounts receivable, net, accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy: · Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities. · Level 2 – Observable inputs other than quoted prices included in Level 1, such as assets or liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. · Level 3 – Unobservable inputs that are supported by little or no market activity and significant to the overall fair value measurement of the assets or liabilities; therefore requiring the company to develop its own valuation techniques and assumptions. As of April 30, 2023 and 2022, we did not have any Level 2 or Level 3 financial assets and our cash equivalents of $ 28.7 million 116.3 million Stock-Based Compensation We account for stock options, restricted stock units, performance stock units and other stock-based awards granted under our equity compensation plans in accordance with the authoritative guidance of ASC 718, Compensation – Stock Compensation Debt Issuance Costs Debt issuance costs related to convertible senior notes are recorded as a deduction that is netted against the principal value of the debt and are amortized to interest expense using the effective interest method over the contractual term of the debt (Note 3). Debt issuance costs related to the revolving credit facility are included in prepaid expenses and other current assets in the consolidated balance sheet at April 30, 2023 and are amortized to interest expense over the contractual term of the revolving credit facility (Note 3). Advertising Costs Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of income and comprehensive income. For the fiscal years ended April 30, 2023, 2022 and 2021, advertising costs were $ 0.7 million 0.6 million 0.3 million Income Taxes We utilize the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes 115 We are required to file federal and state income tax returns in various jurisdictions. The preparation of these returns requires us to interpret the applicable tax laws in effect in such jurisdictions, which could affect the amount paid by us. Comprehensive Income Comprehensive income is the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income is equal to our net income for all periods presented. Accounting Standards Not Yet Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates |
Debt
Debt | 12 Months Ended |
Apr. 30, 2023 | |
Debt Disclosure [Abstract] | |
Debt | Note 3 – Debt Convertible Senior Notes Due 2026 In March 2021, we issued $ 143.8 million 138.5 million 5.3 million The Convertible Notes are senior unsecured obligations and accrue interest at a rate of 1.25 March 15, 2026 The initial conversion rate for the Convertible Notes is approximately 47.1403 shares of our common stock per $1,000 principal amount, which represents an initial conversion price of approximately $21.21 per share of our common stock. The conversion rate is subject to adjustments upon the occurrence of certain events in accordance with the terms of the Indenture. In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their Convertible Notes in connection with such a fundamental change, as defined in the Indenture. Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding September 15, 2025, only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending July 31, 2021, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the exchange rate on each such trading day; (3) if we call any or all of the Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; and (4) upon the occurrence of specified corporate events as described in the Indenture. On or after September 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders at their option may convert their Convertible Notes at any time, regardless of the foregoing circumstances. We may not redeem the Convertible Notes prior to March 20, 2024. On or after March 20, 2024, the Convertible Notes are redeemable for cash, whole or in part, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding the redemption date. The Indenture contains customary terms and covenants, including that upon certain events of default occurring and continuing, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare the entire principal of all the Convertible Notes plus accrued and unpaid interest to be immediately due and payable. As of April 30, 2023, the conditions allowing holders of the Convertible Notes to convert had not been met and, therefore, the Convertible Notes are classified as a long-term liability on the consolidated balance sheets at April 30, 2023 and 2022. In accounting for the issuance of the Convertible Notes, prior to the adoption of ASU 2020-06, Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity 99.7 million 8.78 44.1 million In accounting for the issuance costs related to the Convertible Notes, prior to the adoption of ASU 2020-06, we allocated the total amount incurred to the debt and equity components of the Convertible Notes based on their relative values. Issuance costs attributable to the debt component were $ 3.7 million 1.6 million On May 1, 2021, we elected to early adopt ASU 2020-06 using the modified retrospective transition method. Under such transition method, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to our adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the re-combination of the debt and equity components of the Convertible Notes into a single debt instrument, which resulted in a $42.4 million decrease in additional paid-in capital from the derecognition of the bifurcated equity component, a $41.6 million increase in convertible senior notes, net from the derecognition of the discount associated with the bifurcated equity component, or debt discount, and $0.8 million decrease to the May 1, 2021 opening balance of accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the Convertible Notes. Additionally, we derecognized the allocation of the issuance costs to the equity component and all issuance costs related to the Convertible Notes are being amortized to interest expense using the effective interest method over the contractual term of the Convertible Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The net carrying amount of the Convertible Notes is as follows (in thousands): Schedule of net carrying amount of the debt component April 30, 2023 April 30, 2022 Principal $ 143,750 $ 143,750 Unamortized issuance costs (3,127 ) (4,173 ) Net carrying amount $ 140,623 $ 139,577 As of April 30, 2023 and 2022, the estimated fair value of the Convertible Notes was approximately $ 157.3 million 167.1 million 100 The following table summarizes the interest expense recognized related to the Convertible Notes for the fiscal years ended April 30, 2023 and 2022 (in thousands): Schedule of interest expenses Fiscal Year Ended April 30, 2023 2022 2021 Contractual interest expense $ 1,395 $ 1,603 $ 245 Amortization of issuance costs 1,046 1,030 54 Amortization of debt discount (1) – – 862 Total interest expense associated with Convertible Notes $ 2,441 $ 2,633 $ 1,161 _______________ (1) As discussed above, the adoption of ASU 2020-06 on May 1, 2021 resulted in the re-combination of the debt and equity components of the Convertible Notes into a single debt instrument. Accordingly, the unamortized debt discount balance and the net carrying amount of the equity component were derecognized. Capped Call Transactions In connection with the issuance of the Convertible Notes, we entered into privately negotiated capped call transactions (the “Capped Calls”) with certain financial institution counterparties (the “Option Counterparties”). We used 12,837 We evaluated the Capped Calls under ASC 815-10 and determined that they should be accounted for as a separate transaction from the Convertible Notes and that the Capped Calls met the criteria for equity classification. Therefore, the cost of $12.8 million to purchase the Capped Calls was recorded as a reduction to additional paid-in capital in the consolidated balance sheet at April 30, 2021. The Capped Calls will not be subsequently remeasured as long as the conditions for equity classification continue to be met. During fiscal years 2023 and 2022, there were no conversions of our Convertible Notes, and therefore, there was no activity with respect to the Capped Calls. We believe the conditions for equity classification continue to be met as of April 30, 2023 and 2022. Revolving Credit Facility On March 14, 2023, we entered into a credit agreement with Bank of America, N.A., as administrative agent and letter of credit issuer (the “Credit Agreement”). The Credit Agreement provides for a revolving credit facility (the “Revolving Credit Facility”) in an amount equal to the lesser of (i) $50 million, and (ii) a borrowing base calculated as the sum of (a) 80% of the value of certain of our eligible accounts receivable, plus (b) up to 100% of the value of eligible cash collateral. The Revolving Credit Facility will mature on March 13, 2024 and is secured by substantially all of our assets. no Loans under the Revolving Credit Facility will bear interest at either (1) a term Secured Overnight Financing Rate (“SOFR”) rate for a specified interest period plus a SOFR adjustment (equal to 0.10%) plus a margin of 1.40% or (2) base rate plus a margin of 0.40% at our option. 0.20 The Credit Agreement includes certain customary affirmative and negative covenants, including limitations on mergers, consolidations and sales of assets, limitations on liens, limitations on certain restricted payments and investments, limitations on transactions with affiliates and limitations on incurring additional indebtedness. In addition, the Credit Agreement requires maintenance of a minimum consolidated EBITDA, as defined in the Credit Agreement, of $ 15 The Credit Agreement also provides for certain customary events of defaults, including, among others, failure to make payments, breach of representations and warranties, and default of convenants. |
Leases
Leases | 12 Months Ended |
Apr. 30, 2023 | |
Leases | |
Leases | Note 4 – Leases We currently lease certain office, manufacturing, laboratory and warehouse space located in Orange County, California under operating lease agreements. Our leased facilities have original lease terms ranging from 7 to 12 years, contain multi-year renewal options, and scheduled rent increases of 3% on either an annual or biennial basis. Multi-year renewal options were included in determining the right-of-use asset and lease liability for three of our leases as we considered it reasonably certain that we would exercise such renewal options. In addition, certain of our leases provide for periods of free rent, lessor improvements and tenant improvement allowances, of which certain of these improvements have been classified as leasehold improvements and/or are being amortized over the shorter of the estimated useful life of the improvements or the remaining life of the lease. Certain of our operating facility leases require us to pay property taxes, insurance and common area maintenance. While these payments are not included as part of our lease liabilities, they are recognized as variable lease cost in the period they are incurred. We also lease certain manufacturing equipment under a 5-year finance lease that commenced in the second quarter of fiscal year 2022. The components of our lease costs for the fiscal years ended April 30, 2023, 2022 and 2021, were as follows (in thousands): Schedule of lease costs Fiscal Year Ended April 30, 2023 2022 2021 Operating lease cost $ 4,386 $ 3,872 $ 3,151 Variable lease cost 1,408 944 676 Short-term lease cost 576 515 388 Finance lease costs: Amortization of right-of-use assets 216 43 82 Interest on lease liabilities 125 47 4 Total lease costs $ 6,711 $ 5,421 $ 4,301 Supplemental consolidated balance sheet and other information related to our leases as of April 30, 2023 and 2022 were as follows (in thousands, except weighted average data): Balance sheet classification of leases April 30, Leases Classification 2023 2022 Assets Operating Operating lease right-of-use assets $ 42,772 $ 36,806 Finance Property and equipment, net 2,529 2,728 Total leased assets $ 45,301 $ 39,534 Liabilities Current: Operating Current portion of operating lease liabilities $ 1,358 $ 2,969 Finance Other current liabilities 531 505 Non-current: Operating Operating lease liabilities, less current portion 45,690 37,886 Finance Finance lease liabilities, less current portion 1,562 2,093 Total lease liabilities $ 49,141 $ 43,453 Operating and finance leases Weighted average remaining lease term (years): Operating leases 16.6 12.4 Finance lease 3.7 4.7 Weighted average discount rate Operating leases 6.0 3.3 Finance lease 5.3 5.3 Supplemental cash flow information related to our leases were as follows (in thousands): Schedule of supplemental cash flow information related to leases Fiscal Year Ended April 30, 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 4,069 $ 2,376 $ 2,972 Operating cash flows from finance leases 125 47 5 Financing cash flows from finance leases 505 162 93 Non-cash transactions: Right-of-use assets obtained upon operating lease modifications and reassessments, net $ 9,267 $ 4,554 $ – Right-of-use assets obtained in exchange for operating lease obligations $ – $ 16,093 $ – Decapitalization of right-of-use assets upon impairment $ 89 $ – $ – Property and equipment obtained in exchange for finance lease obligation $ – $ 2,760 $ – As of April 30, 2023, the maturities of our lease liabilities, which includes those derived from lease renewal options that we considered it reasonably certain that we would exercise, were as follows (in thousands): Schedule of maturities of operating lease liabilities Fiscal Year Ending April 30, Operating Leases Finance Lease Total 2024 $ 4,140 $ 629 $ 4,769 2025 4,060 629 4,689 2026 4,167 629 4,796 2027 4,199 419 4,618 2028 4,036 – 4,036 Thereafter 56,418 – 56,418 Total lease payments $ 77,020 $ 2,306 $ 79,326 Less: imputed interest (29,972 ) (213 ) (30,185 ) Total lease liabilities $ 47,048 $ 2,093 $ 49,141 |
Stockholders_ Equity
Stockholders’ Equity | 12 Months Ended |
Apr. 30, 2023 | |
Equity [Abstract] | |
Stockholders’ Equity | Note 5 – Stockholders’ Equity Series E Preferred Stock Redemption and Dividends During the fourth quarter of fiscal 2021 and prior to the redemption discussed below, holders of our 10.50% Series E Convertible Preferred Stock (the “Series E Preferred Stock”) converted an aggregate of 28,168 33,514 21.00 On April 12, 2021 (the “Redemption Date”), we redeemed all then current remaining outstanding shares of our Series E Preferred Stock at a per share price equal to the $ 25.00 3.4 million Holders of our Series E Preferred Stock were entitled to receive cumulative dividends at the rate of 10.50% per annum based on the liquidation preference of $ 25.00 2.625 0.08021 4.5 million No Sale of Common Stock During the third quarter of fiscal 2021, we completed an underwritten public offering pursuant to which we sold 3,833,335 9.00 500,000 34.5 million 2.4 million During the fiscal years ended April 30, 2023 and 2022, we had no Shares of Common Stock Authorized and Reserved for Future Issuance As of April 30, 2023, 62,691,885 Our common stock outstanding as of April 30, 2023 excluded the following shares of common stock reserved for future issuance (in thousands): Schedule of common stock reserved for future issuance Shares Stock Incentive Plans 8,338 Employee Stock Purchase Plan 963 Conversion of Convertible Notes 6,776 Total common stock reserved for future issuance 16,077 |
Equity Compensation Plans
Equity Compensation Plans | 12 Months Ended |
Apr. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Equity Compensation Plans | Note 6 – Equity Compensation Plans Stock Incentive Plans The Avid Bioservices, Inc. 2018 Omnibus Incentive Plan (the “2018 Plan”) is a stockholder-approved plan, which provides, among other things, the ability for us to grant stock options, restricted stock units, performance stock units and other forms of stock-based awards. The 2018 Plan replaced our 2009, 2010 and 2011 Stock Incentive Plans (the “Prior Plans”). However, any awards outstanding under the Prior Plans as of the 2018 Plan’s effective date continue to remain subject to and be paid under the applicable Prior Plan, and any shares subject to outstanding awards under the Prior Plans that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2018 Plan. In October 2021, our stockholders approved an amendment to the 2018 Plan to increase the number of authorized shares reserved for issuance under the 2018 plan by 3.4 million The 2018 Plan and the Prior Plans are collectively referred to as the “Stock Plans”. As of April 30, 2023, we had an aggregate of 8,337,807 3,926,550 4,411,257 Stock Options We ceased granting stock options during fiscal 2022. Stock options previously granted under our Stock Plans were granted at an exercise price not less than the fair market value of our common stock on the date of grant. Stock options granted to employees generally vest over a four-year period from the date of grant and stock options granted to non-employee directors generally vest over a period of one to three years from the date of grant. Stock options granted under the 2018 Plan have a contractual term of seven years; however, the maximum contractual term of any stock option granted under the Stock Plans is ten years. The estimated fair value of stock options is measured at the grant date, using a fair value-based method, such as a Black-Scholes option valuation model, and is amortized as stock-based compensation expense on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The use of a valuation model requires us to make certain estimates and assumptions with respect to selected model inputs. The expected volatility is based on the daily historical volatility of our common stock covering the estimated expected term. The expected term of options granted reflects actual historical exercise activity and assumptions regarding future exercise activity of unexercised, outstanding options. The risk-free interest rate is based on U.S. Treasury notes with terms within the contractual life of the option at the time of grant. The expected dividend yield assumption is based on our expectation of future dividend payouts. We have never declared or paid any cash dividends on our common stock and currently do not anticipate paying such cash dividends. There were no Schedule of fair value assumptions for options Fiscal Year Ended April 30, 2022 2021 Risk-free interest rate 0.86 0.32 Expected life (in years) 4.37 4.69 Expected volatility 68.64 81.42 Expected dividend yield – – The following summarizes our stock option transaction activity for the fiscal year ended April 30, 2023: Schedule of stock option activity Stock Options (in thousands) Grant Date Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at May 1, 2022 2,505 $ 6.88 Granted – – Exercised (366 ) $ 7.06 Canceled or expired (60 ) $ 9.89 Outstanding at April 30, 2023 2,079 $ 6.76 3.69 $ 23,654 Vested and expected to vest 2,079 $ 6.76 3.69 $ 23,654 Exercisable at April 30, 2023 1,595 $ 6.52 3.59 $ 18,447 ______________ (1) Aggregate intrinsic value represents the difference between the exercise price of an option and the closing market price of our common stock on April 28, 2023 (the last trading day of fiscal year 2023), which was $18.05 per share. The weighted-average grant date fair value of stock options granted during the fiscal years ended April 30, 2022 and 2021 was $ 13.09 4.74 no The aggregate intrinsic value of stock options exercised during the fiscal years ended April 30, 2023, 2022 and 2021 was $ 3.5 million 8.1 million 3.9 million 2.6 million 2.7 million 3.6 million We issue shares of common stock that are reserved for issuance under the Stock Plans upon the exercise of stock options, and we do not expect to repurchase shares of common stock from any source to satisfy our obligations under our compensation plans. As of April 30, 2023, the total estimated unrecognized compensation cost related to non-vested stock options was $1.3 million. This cost is expected to be recognized over a weighted average vesting period of 0.99 Restricted Stock A restricted stock unit (“RSU”) represents the right to receive one share of our common stock upon the vesting of such unit. RSUs granted to employees generally vest over a four-year period from the date of grant and RSUs granted to non-employee directors generally vest over a period of one to three years from the date of grant. The estimated fair value of RSUs is based on the closing market value of our common stock on the date of grant and is amortized as stock-based compensation expense on a straight-line basis over the period of vesting. The following summarizes our RSUs transaction activity for the fiscal year ended April 30, 2023: Schedule of RSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 642 $ 14.89 Granted 780 $ 17.63 Vested (366 ) $ 15.09 Forfeited (50 ) $ 17.32 Outstanding at April 30, 2023 1,006 $ 16.83 The weighted-average grant date fair value of RSUs granted during the fiscal years ended April 30, 2023, 2022 and 2021 was $ 17.63 25.20 7.29 The total fair value of RSUs vested during the fiscal years ended April 30, 2023, 2022 and 2021 was $ 6.3 million 5.5 million 0.7 million As of April 30, 2023, the total estimated unrecognized compensation cost related to non-vested RSUs was $ 15.4 million 2.53 Performance Stock Units The Compensation Committee of the Board of Directors grants PSUs to our executives. The PSUs are subject to annual vesting over three consecutive fiscal year performance periods with the first one-third vesting on April 30 of the year following the grant date, and each successive one-third vesting on April 30 of the following two years respectively (each a “Performance Period”). Each PSU that vests represent the right to receive one share of our common stock. The number of shares that will vest for each Performance Period, if any, is based upon the attainment of certain predetermined financial metrics for each such Performance Period. Depending on the actual financial metrics achieved relative to the target financial metrics for such Performance Periods, the number of PSUs issued could range from 0% to 200% of the target amount. The number of granted shares included in the table below is based on a maximum 200% achievement of each financial metric during each Performance Period (the “Maximum Performance Target”). If a financial metric is achieved at a rate below the Maximum Performance Target, or is not achieved, the corresponding portion of the PSUs that do not vest are forfeited. The following summarizes our PSUs transaction activity for the fiscal year ended April 30, 2023: Schedule of PSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 233 $ 25.31 Granted 608 $ 18.09 Vested (161 ) $ 20.75 Forfeited (158 ) $ 20.69 Outstanding at April 30, 2023 522 $ 19.70 The weighted-average grant date fair value of PSUs granted during the fiscal years ended April 30, 2023 and 2022, was $ 18.09 25.36 no The total fair value of PSUs vested during the fiscal years ended April 30, 2023 and 2022 was $ 3.3 million 2.1 million No As of April 30, 2023, there was $ 10.3 million 1.39 Employee Stock Purchase Plan The Avid Bioservices, Inc. 2010 Employee Stock Purchase Plan (the “ESPP”) is a stockholder-approved plan under which employees can purchase shares of our common stock, based on a percentage of their compensation, subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the first trading day of the six-month offering period or on the last trading day of the six-month offering period. Offering Periods commence on or about the first day of January and July of each year. During the fiscal years ended April 30, 2023, 2022 and 2021, a total of 68,646 44,364 72,409 12.22 14.50 5.84 The fair value of the shares purchased under the ESPP was determined using a Black-Scholes option valuation model (see explanation of valuation model inputs above under “Stock Options”) and is recognized as expense on a straight-line basis over the requisite service period (or six-month offering period). The weighted average grant date fair value of purchase rights under the ESPP during fiscal years ended April 30, 2023, 2022 and 2021 was $ 4.93 8.62 3.17 Schedule of ESPP Fair value assumptions Fiscal Year Ended April 30, 2023 2022 2021 Risk-free interest rate 3.76 0.15 0.14 Expected life (in years) 0.50 0.50 0.50 Expected volatility 68.60 59.91 75.50 Expected dividend yield – – – Stock-based Compensation Expense Stock-based compensation expense included in our consolidated statements of income and comprehensive income was comprised of the following (in thousands): Schedule of share-based compensation expense Fiscal Year Ended April 30, 2023 2022 2021 Cost of revenues $ 3,876 $ 2,540 $ 1,404 Selling, general and administrative expense 7,102 4,840 2,450 Total $ 10,978 $ 7,380 $ 3,854 |
Income Taxes
Income Taxes | 12 Months Ended |
Apr. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 7 – Income Taxes Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. At April 30, 2023, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740 wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of our deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of our deferred tax assets, management considers all available evidence, both positive and negative. Management’s evaluation placed significant emphasis on guidance in ASC 740, which states that “a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.” In fiscal 2022, we transitioned from a cumulative loss in recent years to cumulative income. This transition coupled with additional positive evidence enabled us to fully release our valuation allowance as of April 30, 2022. We maintained the same position that our deferred tax assets did not require a valuation allowance as of April 30, 2023. The valuation allowance did no 127,672 11.3 We are subject to taxation in the United States and various states jurisdictions. We have not been notified that we are under audit by the IRS or any state taxing authorities and our federal and state returns from April 30, 2020 and April 30, 2019, respectively, remain open for examination. Due to the presence of net operating loss (“NOL”) carryforwards the tax authorities can also examine years prior to the standard statue of limitations. At April 30, 2023, we had federal NOL carry forwards of approximately $ 442.4 million 294.7 million 0.9 million Additionally, the future utilization of our NOL carry forwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Section 382, as a result of ownership changes. A Section 382 analysis has been completed through April 30, 2022, and it was determined that no significant change in ownership had occurred. However, ownership changes occurring subsequent to April 30, 2022 may impact the utilization of NOL carry forwards and other tax attributes in future periods. At April 30, 2023, we had $ 5.8 million 1.5 million The provision for income taxes on our net income before income taxes for the fiscal years ended April 30, 2023, 2022 and 2021 is comprised of the following (in thousands): Schedule of provision for income taxes 2023 2022 2021 Federal income taxes at statutory rate $ 421 $ 2,659 $ 2,355 State income taxes, net of valuation allowance 301 605 – Expiration and adjustments of deferred tax assets – – 451 Change in federal valuation allowance – (122,703 ) 2,450 Stock-based compensation including 162M limitations 615 (1,153 ) (240 ) Research and development credits – – (4,958 ) Adjustment for federal benefit of state – 5,326 – Permanent differences 66 425 4 Other, net 40 (170 ) (62 ) Income tax expense (benefit) $ 1,443 $ (115,011 ) $ – Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and deferred tax liabilities at April 30, 2023 and 2022 are as follows (in thousands): Schedule of deferred tax assets and deferred tax liabilities 2023 2022 Net operating losses $ 112,194 $ 99,710 Research and development credits 5,569 5,550 Stock-based compensation 2,589 2,710 Deferred revenue 2,420 5,494 Lease liabilities 12,742 11,107 Accrued liabilities 2,248 785 Accrued compensation 1,781 1,705 Total deferred tax assets 139,543 127,061 Less valuation allowance – – Total deferred tax assets, net of valuation allowance 139,543 127,061 Deferred tax liabilities: Fixed assets (14,320 ) (1,972 ) ROU assets (11,584 ) (10,007 ) Total deferred tax liabilities (25,904 ) (11,979 ) Net deferred tax assets $ 113,639 $ 115,082 In accordance with ASC 740, we are required to recognize the impact of an uncertain tax position in the consolidated financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained upon examination by the tax authorities. Unrecognized tax positions at April 30, 2023 and 2022 are as follows (in thousands): Schedule of unrecognized tax positions 2023 2022 Unrecognized tax positions, beginning of year $ 5,133 $ 1,600 Gross (decrease) increase – prior period tax positions (1,693 ) 3,533 Unrecognized tax positions, end of year $ 3,440 $ 5,133 If recognized, the unrecognized tax positions will impact our income tax benefit or effective tax rate. We do not expect any significant increases or decreases to our unrecognized tax positions within the next 12 months. It is our policy to recognize interest and penalties related to income tax matters in interest expense and other income (expense), net, respectively, in our consolidated statements of income and comprehensive income. For the fiscal years ended April 30, 2023 and 2021, we did not incur any interest or penalties. For the fiscal year ended April 30, 2022, we recognized an immaterial amount of interest and penalties. |
Net Income Per Common Share
Net Income Per Common Share | 12 Months Ended |
Apr. 30, 2023 | |
Net income per share attributable to common stockholders: | |
Net Income Per Common Share | Note 8 – Net Income Per Common Share Basic net income per common share is computed by dividing our net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing our net income attributable to common stockholders by the sum of the weighted average number of shares of common stock outstanding during the period plus the potential dilutive effects of stock options, unvested RSUs and PSUs, shares of common stock expected to be issued under our ESPP, Convertible Notes and Series E Preferred Stock outstanding during the period. Net income attributable to common stockholders represents our net income less Series E Preferred Stock accumulated dividends and the impact of Series E Preferred Stock redemption. The potential dilutive effect of stock options, unvested RSUs and PSUs, and shares of common stock expected to be issued under our ESPP during the period are calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. The potential dilutive effect of our Convertible Notes and Series E Preferred Stock outstanding during the period are calculated using the if-converted method assuming the conversion of our Convertible Notes and Series E Preferred Stock as of the earliest period reported or at the date of issuance, if later, but are excluded if their effect is anti-dilutive. A reconciliation of the numerators and the denominators of the basic and dilutive net income per common share computations are as follows (in thousands, except per share amounts): Schedule of earnings per share, basic and diluted Fiscal Year Ended April 30, 2023 2022 2021 Numerator Net income $ 560 $ 127,672 $ 11,212 Series E preferred stock accumulated dividends – – (4,455 ) Impact of Series E preferred stock redemption – – (3,439 ) Net income attributable to common stockholders, basic $ 560 $ 127,672 $ 3,318 Add interest expense on Convertible Notes, net of tax – 1,954 – Net income attributable to common stockholders, diluted $ 560 $ 129,626 $ 3,318 Denominator Weighted average basic common shares outstanding 62,268 61,484 58,222 Effect of dilutive securities: Stock options 1,248 1,830 909 RSUs, PSUs and ESPP 266 384 295 Convertible Notes – 6,776 – Weighted average dilutive common shares outstanding 63,782 70,474 59,426 Net income per share attributable to common stockholders: Basic $ 0.01 $ 2.08 $ 0.06 Diluted $ 0.01 $ 1.84 $ 0.06 The following table presents the potential dilutive securities excluded from the calculation of diluted net income per common share for the periods presented as the effect of their inclusion would have been anti-dilutive (in thousands): Schedule of antidilutive shares Fiscal Year Ended April 30, 2023 2022 2021 Stock options 46 43 829 RSUs, PSUs and ESPP 253 9 – Convertible Notes 6,776 – 928 Series E Preferred Stock – – 1,864 Total 7,075 52 3,621 |
Employee Benefit Plan
Employee Benefit Plan | 12 Months Ended |
Apr. 30, 2023 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plan | Note 9 – Employee Benefit Plan We maintain a 401(k) Plan pursuant to section 401(k) of the Internal Revenue Code that allows participating employees to defer a portion of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code. We are not required to make matching contributions under the 401(k) Plan. However, we match 50% of employee contributions of up to 6% of their annual eligible compensation. Total expense recognized by us for matching contributions to the 401(k) Plan for the fiscal years ended April 30, 2023, 2022 and 2021 was $ 0.9 million 0.6 million 0.5 million |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Apr. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 10 – Commitments and Contingencies In the ordinary course of business, we are at times subject to various legal proceedings and disputes. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions, if any, are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. We currently are not a party to legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated financial condition or results of operations. Humanigen Arbitration On December 17, 2021, we filed a Demand for Arbitration claiming more than $20.5 million in damages against Humanigen, Inc. (“Humanigen”) with the American Arbitration Association (“AAA”) entitled, Avid Bioservices, Inc. v. Humanigen, Inc. (AAA Case No. 01-21-0018-0523). The Demand contains three claims for: (1) breach of contract concerning the process development and manufacturing master services agreement (“MSA”); (2) anticipatory breach of contract concerning the capacity expansion and contribution/commitment letter (“Letter Agreement”); and (3) trade libel and commercial disparagement. On January 6, 2022, Humanigen filed an Answer to our Demand, denying the allegations and asserting affirmative defenses. On July 1, 2022, Humanigen filed its counterclaims against us in the form of a complaint in the Orange County Superior Court (Case No. 30-2022-01268184) alleging three claims for (1) breach of the MSA seeking return or reimbursement of the amounts Humanigen paid us before cancelling the MSA, (2) declaratory relief that Humanigen has no remaining obligations under the Letter Agreement, and (3) unfair business practices. On July 19, 2022, we filed a motion with the state court to compel all claims by Humanigen against us to arbitration before the AAA. On October 17, 2022, the state court granted our motion to compel all of Humanigen’s claims against us to arbitration and denied Humanigen’s motion to stay the arbitration. As a result of the court having granted our motion, on November 3, 2022, Humanigen filed its Demand for Arbitration realleging the breach of the MSA and unfair business practices claims which it had initially filed in state court. On November 10, 2022, we filed an Answer to Humanigen’s Demand, denying the allegations and asserting affirmative defenses. On February 21, 2023, we entered into a Confidential Settlement and Mutual Releases Agreement with Humanigen resolving the arbitration proceeding and all disputes between the parties. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Apr. 30, 2023 | |
Accounting Policies [Abstract] | |
Cash and Cash Equivalents | Cash and Cash Equivalents We consider all short-term investments readily convertible to cash, without notice or penalty, with an initial maturity of 90 days or less to be cash equivalents. |
Restricted Cash | Restricted Cash Under the terms of an operating lease related to one of our facilities (Note 4), we are required to maintain a letter of credit as collateral. Accordingly, at April 30, 2023 and 2022, restricted cash of $ 0.4 million The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Schedule of restricted cash As of April 30, 2023 2022 2021 Cash and cash equivalents $ 38,542 $ 126,166 $ 169,915 Restricted cash 350 350 350 Total cash, cash equivalents and restricted cash $ 38,892 $ 126,516 $ 170,265 |
Revenue Recognition | Revenue Recognition We recognize revenue in accordance with the authoritative guidance of ASC 606, Revenue from Contracts with Customers Revenue recognized from services provided under our customer contracts is disaggregated into manufacturing and process development revenue streams. Manufacturing revenue Manufacturing revenue generally represents revenue from the manufacturing of customer products recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a manufacturing contract, a quantity of manufacturing runs are ordered at a specified scale with prescribed delivery dates, where the product is manufactured according to the customer’s specifications and typically includes only one performance obligation. Each manufacturing run represents a distinct service that is sold separately and has stand-alone value to the customer. The products are manufactured exclusively for a specific customer and have no alternative use. The customer retains control of its product during the entire manufacturing process and can make changes to the process or specifications at its request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. Process development revenue Process development revenue generally represents revenue from services associated with the custom development of a manufacturing process and analytical methods for a customer’s product. Process development revenue is recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a process development contract, the customer owns the product details and process, which has no alternative use. These process development projects are customized to each customer to meet its specifications and typically includes only one performance obligation. Each process represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by our services and can make changes to its process or specifications upon request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. The following table summarizes our manufacturing and process development revenue streams (in thousands): Disaggregation of revenue Fiscal Year Ended April 30, 2023 2022 2021 Manufacturing revenues $ 125,416 $ 99,282 $ 83,678 Process development revenues 23,850 20,315 12,190 Total revenues $ 149,266 $ 119,597 $ 95,868 The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets (unbilled receivables), and contract liabilities (customer deposits and deferred revenue). Contract assets are recorded when our right to consideration is conditioned on something other than the passage of time. Contract assets are reclassified to accounts receivable on the consolidated balance sheet when our rights become unconditional. Contract liabilities represent customer deposits and deferred revenue billed and/or received in advance of our fulfillment of performance obligations. Contract liabilities convert to revenue as we perform our obligations under the contract. During the fiscal years ended April 30, 2023 and 2022, we recognized revenue of $ 40.8 million 34 The transaction price for services provided under our customer contracts reflects our best estimates of the amount of consideration to which we are entitled in exchange for providing goods and services to our customers. For contracts with multiple performance obligations, we allocate transaction price to each performance obligation identified in a contract on a relative standalone selling price basis. We generally determine relative standalone selling prices based on the price observed in the customer contract for each distinct performance obligation. If observable standalone selling prices are not available, we may estimate the applicable standalone selling price based on the pricing of other comparable services or on a price that we believe the market is willing to pay for the applicable service. In determining the transaction price, we also considered the different sources of variable consideration including, but not limited to, discounts, credits, refunds, price concessions or other similar items. We have included in the transaction price some or all of an amount of variable consideration, utilizing the most likely method, only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The actual amount of consideration ultimately received may differ. In addition, our customer contracts generally include provisions entitling us to a cancellation or postponement fee when a customer cancels or postpones its commitments prior to our initiation of services, therefore not utilizing their reserved capacity. The determination of such cancellation and postponement fees are based on the terms stated in the related customer contract but are generally considered substantive for accounting purposes and create an enforceable right and obligation due to us when the cancellation or postponement occurs. Accordingly, we recognize such fees, subject to variable consideration, as revenue upon the cancellation or postponement date utilizing the most likely method. Management may be required to exercise judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations, estimating variable consideration, and estimating the progress towards the satisfaction of performance obligations. If actual results in the future vary from our estimates, the estimates will be adjusted, which will affect revenues in the period that such variances become known. During the fiscal year ended April 30, 2023, we recognized revenue of $ 3.0 million 14.7 million We apply the practical expedient available under ASC 606 that permits us not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. As of April 30, 2023, we do not have any unsatisfied performance obligations for contracts greater than one year. Costs incurred to obtain a contract are not material. These costs are generally employee sales commissions, which are expensed as incurred and included in selling, general and administrative expense in the consolidated statements of income and comprehensive income. |
Accounts Receivable, Net | Accounts Receivable, Net Accounts receivable is primarily comprised of amounts owed to us for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for doubtful accounts, if necessary. We apply judgment in assessing the ultimate realization of our receivables and we estimate an allowance for doubtful accounts based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. Based on our analysis of our accounts receivable balance as of April 30, 2023, we determined an allowance for doubtful accounts of $ 0.5 million Based on our analysis of our accounts receivable balance as of April 30, 2022, we determined an allowance for doubtful accounts of $ 18.4 million |
Concentrations of Credit Risk and Customer Base | Concentrations of Credit Risk and Customer Base Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents, accounts receivable, net and contract assets. As of April 30, 2023 and 2022, we maintain our cash balances primarily with a major commercial bank and our deposits held with the bank exceed the amount of government insurance limits provided on our deposits. We are exposed to credit risk in the event of default by the major commercial bank holding our cash balances to the extent of the cash amounts recorded on the accompanying consolidated balance sheets exceed the amount of government insurance limits provided on our deposits. Our accounts receivable from amounts billed for services provided under customer contracts are derived from a limited number of customers. Most customer contracts require up-front payments and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs. At April 30, 2023 and 2022, approximately 76% and 84%, respectively, of our accounts receivable, net were due from our top ten customers. Our revenues are derived from a limited number of customers. Historically, these customers have not entered into long-term contracts because their need for drug supply depends on a variety of factors, including a product’s stage of development, the timing of regulatory filings and approvals, the product needs of their collaborators, if applicable, their financial resources and the market demand with respect to a commercial product. The table below identifies each of our customers that accounted for 10% or more of our total revenues during any of the fiscal years ended April 30, 2023, 2022 and 2021: Concentration of revenues Customer Geographic Location 2023 2022 2021 Halozyme Therapeutics, Inc. (1) U.S. 53 % 41 % 51 % IGM Biosciences, Inc. U.S. * 11 * Gilead Sciences, Inc. U.S. – * 16 ______________ (1) Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates. * Represents a percentage less than 10% of our total revenues. We attribute revenue to the individual countries where the customer is headquartered. Approximately 100 |
Leases | Leases We account for our leases in accordance with the authoritative guidance of ASC 842, Leases Our operating leases may include options to extend the lease which are included in the lease term when it is reasonably certain that we will exercise a renewal option. Operating lease expense is recognized on a straight-line basis over the expected lease term. Our finance lease with a term greater than one year is included as an asset within property and equipment, net and a lease liability equal to the present value of the minimum lease payments is included in other current liabilities and finance lease liabilities, less current portion in our consolidated balance sheets. The present value of the finance lease payments is calculated using the implicit interest rate in the lease. Finance lease ROU assets are amortized on a straight-line basis over the expected useful life of the asset and the carrying amount of the lease liability is adjusted to reflect interest, which is recorded as interest expense. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets and lease expense for these short-term leases is recognized on a straight-line basis over the lease term. We have also elected the practical expedient to not separate lease components from non-lease components. |
Inventory | Inventory Inventory consists of raw materials inventory and is valued at the lower of cost, determined by the first-in, first-out method, or net realizable value. We periodically review raw materials inventory for potential impairment and adjust inventory to its net realizable value based on the estimate of future use and reduce the carrying value of inventory as deemed necessary. |
Property and Equipment | Property and Equipment Property and equipment is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related asset, which are generally as follows: Schedule of estimated useful lives of property Description Estimated Useful Life Leasehold improvements Shorter of estimated useful life or lease term Laboratory and manufacturing equipment 5 – 15 years Computer equipment and software 3 – 5 years Furniture, fixtures and office equipment 5 – 10 years Costs for property and equipment not yet placed into service have been capitalized as construction-in-progress. These costs are primarily related to equipment and leasehold improvements associated with our manufacturing facilities, and will be depreciated in accordance with the above guidelines once placed into service. Interest costs incurred during construction of major capital projects are capitalized as construction-in-progress until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Interest capitalized as construction-in-progress for the fiscal years ended April 30, 2023 and 2022, was $ 0.4 million 0.2 million Schedule of property and equipment April 30, 2023 2022 Leasehold improvements $ 97,514 $ 37,345 Laboratory and manufacturing equipment 35,501 30,089 Computer equipment and software 5,028 5,326 Furniture, fixtures and office equipment 1,681 843 Construction-in-progress 68,013 43,809 Total property and equipment, gross 207,737 117,412 Less: accumulated depreciation and amortization (30,368 ) (24,457 ) Total property and equipment, net $ 177,369 $ 92,955 Depreciation and amortization expense for the fiscal years ended April 30, 2023, 2022 and 2021 was $ 7.2 million 4.5 million 3.5 million |
Capitalized Software Implementation Cost | Capitalized Software Implementation Cost We capitalize certain implementation costs incurred under cloud computing hosting arrangements. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within other assets on the accompanying consolidated balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. |
Impairment | Impairment Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. If such events or changes in circumstances arise, we compare the carrying amount of the long-lived assets to the estimated future undiscounted cash flows expected to be generated by the long-lived assets. If the long-lived assets are determined to be impaired, any excess of the carrying value of the long-lived assets over its estimated fair value is recognized as an impairment loss. For the fiscal year ended April 30, 2023, there were indicators of impairment of the value of certain long-lived assets that resulted in an impairment loss of $ 0.1 million no |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The carrying amounts in the accompanying consolidated balance sheets for cash and cash equivalents, restricted cash, accounts receivable, net, accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy: · Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities. · Level 2 – Observable inputs other than quoted prices included in Level 1, such as assets or liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. · Level 3 – Unobservable inputs that are supported by little or no market activity and significant to the overall fair value measurement of the assets or liabilities; therefore requiring the company to develop its own valuation techniques and assumptions. As of April 30, 2023 and 2022, we did not have any Level 2 or Level 3 financial assets and our cash equivalents of $ 28.7 million 116.3 million |
Stock-Based Compensation | Stock-Based Compensation We account for stock options, restricted stock units, performance stock units and other stock-based awards granted under our equity compensation plans in accordance with the authoritative guidance of ASC 718, Compensation – Stock Compensation |
Debt Issuance Costs | Debt Issuance Costs Debt issuance costs related to convertible senior notes are recorded as a deduction that is netted against the principal value of the debt and are amortized to interest expense using the effective interest method over the contractual term of the debt (Note 3). Debt issuance costs related to the revolving credit facility are included in prepaid expenses and other current assets in the consolidated balance sheet at April 30, 2023 and are amortized to interest expense over the contractual term of the revolving credit facility (Note 3). |
Advertising Costs | Advertising Costs Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of income and comprehensive income. For the fiscal years ended April 30, 2023, 2022 and 2021, advertising costs were $ 0.7 million 0.6 million 0.3 million |
Income Taxes | Income Taxes We utilize the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes 115 We are required to file federal and state income tax returns in various jurisdictions. The preparation of these returns requires us to interpret the applicable tax laws in effect in such jurisdictions, which could affect the amount paid by us. |
Comprehensive Income | Comprehensive Income Comprehensive income is the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income is equal to our net income for all periods presented. |
Accounting Standards Not Yet Adopted | Accounting Standards Not Yet Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Apr. 30, 2023 | |
Accounting Policies [Abstract] | |
Schedule of restricted cash | Schedule of restricted cash As of April 30, 2023 2022 2021 Cash and cash equivalents $ 38,542 $ 126,166 $ 169,915 Restricted cash 350 350 350 Total cash, cash equivalents and restricted cash $ 38,892 $ 126,516 $ 170,265 |
Disaggregation of revenue | Disaggregation of revenue Fiscal Year Ended April 30, 2023 2022 2021 Manufacturing revenues $ 125,416 $ 99,282 $ 83,678 Process development revenues 23,850 20,315 12,190 Total revenues $ 149,266 $ 119,597 $ 95,868 |
Concentration of revenues | Concentration of revenues Customer Geographic Location 2023 2022 2021 Halozyme Therapeutics, Inc. (1) U.S. 53 % 41 % 51 % IGM Biosciences, Inc. U.S. * 11 * Gilead Sciences, Inc. U.S. – * 16 ______________ (1) Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates. * Represents a percentage less than 10% of our total revenues. |
Schedule of estimated useful lives of property | Schedule of estimated useful lives of property Description Estimated Useful Life Leasehold improvements Shorter of estimated useful life or lease term Laboratory and manufacturing equipment 5 – 15 years Computer equipment and software 3 – 5 years Furniture, fixtures and office equipment 5 – 10 years |
Schedule of property and equipment | Schedule of property and equipment April 30, 2023 2022 Leasehold improvements $ 97,514 $ 37,345 Laboratory and manufacturing equipment 35,501 30,089 Computer equipment and software 5,028 5,326 Furniture, fixtures and office equipment 1,681 843 Construction-in-progress 68,013 43,809 Total property and equipment, gross 207,737 117,412 Less: accumulated depreciation and amortization (30,368 ) (24,457 ) Total property and equipment, net $ 177,369 $ 92,955 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Apr. 30, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of net carrying amount of the debt component | Schedule of net carrying amount of the debt component April 30, 2023 April 30, 2022 Principal $ 143,750 $ 143,750 Unamortized issuance costs (3,127 ) (4,173 ) Net carrying amount $ 140,623 $ 139,577 |
Schedule of interest expenses | Schedule of interest expenses Fiscal Year Ended April 30, 2023 2022 2021 Contractual interest expense $ 1,395 $ 1,603 $ 245 Amortization of issuance costs 1,046 1,030 54 Amortization of debt discount (1) – – 862 Total interest expense associated with Convertible Notes $ 2,441 $ 2,633 $ 1,161 _______________ (1) As discussed above, the adoption of ASU 2020-06 on May 1, 2021 resulted in the re-combination of the debt and equity components of the Convertible Notes into a single debt instrument. Accordingly, the unamortized debt discount balance and the net carrying amount of the equity component were derecognized. |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Apr. 30, 2023 | |
Leases | |
Schedule of lease costs | Schedule of lease costs Fiscal Year Ended April 30, 2023 2022 2021 Operating lease cost $ 4,386 $ 3,872 $ 3,151 Variable lease cost 1,408 944 676 Short-term lease cost 576 515 388 Finance lease costs: Amortization of right-of-use assets 216 43 82 Interest on lease liabilities 125 47 4 Total lease costs $ 6,711 $ 5,421 $ 4,301 |
Balance sheet classification of leases | Balance sheet classification of leases April 30, Leases Classification 2023 2022 Assets Operating Operating lease right-of-use assets $ 42,772 $ 36,806 Finance Property and equipment, net 2,529 2,728 Total leased assets $ 45,301 $ 39,534 Liabilities Current: Operating Current portion of operating lease liabilities $ 1,358 $ 2,969 Finance Other current liabilities 531 505 Non-current: Operating Operating lease liabilities, less current portion 45,690 37,886 Finance Finance lease liabilities, less current portion 1,562 2,093 Total lease liabilities $ 49,141 $ 43,453 |
Operating and finance leases | Operating and finance leases Weighted average remaining lease term (years): Operating leases 16.6 12.4 Finance lease 3.7 4.7 Weighted average discount rate Operating leases 6.0 3.3 Finance lease 5.3 5.3 |
Schedule of supplemental cash flow information related to leases | Schedule of supplemental cash flow information related to leases Fiscal Year Ended April 30, 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 4,069 $ 2,376 $ 2,972 Operating cash flows from finance leases 125 47 5 Financing cash flows from finance leases 505 162 93 Non-cash transactions: Right-of-use assets obtained upon operating lease modifications and reassessments, net $ 9,267 $ 4,554 $ – Right-of-use assets obtained in exchange for operating lease obligations $ – $ 16,093 $ – Decapitalization of right-of-use assets upon impairment $ 89 $ – $ – Property and equipment obtained in exchange for finance lease obligation $ – $ 2,760 $ – |
Schedule of maturities of operating lease liabilities | Schedule of maturities of operating lease liabilities Fiscal Year Ending April 30, Operating Leases Finance Lease Total 2024 $ 4,140 $ 629 $ 4,769 2025 4,060 629 4,689 2026 4,167 629 4,796 2027 4,199 419 4,618 2028 4,036 – 4,036 Thereafter 56,418 – 56,418 Total lease payments $ 77,020 $ 2,306 $ 79,326 Less: imputed interest (29,972 ) (213 ) (30,185 ) Total lease liabilities $ 47,048 $ 2,093 $ 49,141 |
Stockholders_ Equity (Tables)
Stockholders’ Equity (Tables) | 12 Months Ended |
Apr. 30, 2023 | |
Equity [Abstract] | |
Schedule of common stock reserved for future issuance | Schedule of common stock reserved for future issuance Shares Stock Incentive Plans 8,338 Employee Stock Purchase Plan 963 Conversion of Convertible Notes 6,776 Total common stock reserved for future issuance 16,077 |
Equity Compensation Plans (Tabl
Equity Compensation Plans (Tables) | 12 Months Ended |
Apr. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of fair value assumptions for options | Schedule of fair value assumptions for options Fiscal Year Ended April 30, 2022 2021 Risk-free interest rate 0.86 0.32 Expected life (in years) 4.37 4.69 Expected volatility 68.64 81.42 Expected dividend yield – – |
Schedule of stock option activity | Schedule of stock option activity Stock Options (in thousands) Grant Date Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at May 1, 2022 2,505 $ 6.88 Granted – – Exercised (366 ) $ 7.06 Canceled or expired (60 ) $ 9.89 Outstanding at April 30, 2023 2,079 $ 6.76 3.69 $ 23,654 Vested and expected to vest 2,079 $ 6.76 3.69 $ 23,654 Exercisable at April 30, 2023 1,595 $ 6.52 3.59 $ 18,447 ______________ (1) Aggregate intrinsic value represents the difference between the exercise price of an option and the closing market price of our common stock on April 28, 2023 (the last trading day of fiscal year 2023), which was $18.05 per share. |
Schedule of RSU activity | Schedule of RSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 642 $ 14.89 Granted 780 $ 17.63 Vested (366 ) $ 15.09 Forfeited (50 ) $ 17.32 Outstanding at April 30, 2023 1,006 $ 16.83 |
Schedule of PSU activity | Schedule of PSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 233 $ 25.31 Granted 608 $ 18.09 Vested (161 ) $ 20.75 Forfeited (158 ) $ 20.69 Outstanding at April 30, 2023 522 $ 19.70 |
Schedule of ESPP Fair value assumptions | Schedule of ESPP Fair value assumptions Fiscal Year Ended April 30, 2023 2022 2021 Risk-free interest rate 3.76 0.15 0.14 Expected life (in years) 0.50 0.50 0.50 Expected volatility 68.60 59.91 75.50 Expected dividend yield – – – |
Schedule of share-based compensation expense | Schedule of share-based compensation expense Fiscal Year Ended April 30, 2023 2022 2021 Cost of revenues $ 3,876 $ 2,540 $ 1,404 Selling, general and administrative expense 7,102 4,840 2,450 Total $ 10,978 $ 7,380 $ 3,854 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Apr. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of provision for income taxes | Schedule of provision for income taxes 2023 2022 2021 Federal income taxes at statutory rate $ 421 $ 2,659 $ 2,355 State income taxes, net of valuation allowance 301 605 – Expiration and adjustments of deferred tax assets – – 451 Change in federal valuation allowance – (122,703 ) 2,450 Stock-based compensation including 162M limitations 615 (1,153 ) (240 ) Research and development credits – – (4,958 ) Adjustment for federal benefit of state – 5,326 – Permanent differences 66 425 4 Other, net 40 (170 ) (62 ) Income tax expense (benefit) $ 1,443 $ (115,011 ) $ – |
Schedule of deferred tax assets and deferred tax liabilities | Schedule of deferred tax assets and deferred tax liabilities 2023 2022 Net operating losses $ 112,194 $ 99,710 Research and development credits 5,569 5,550 Stock-based compensation 2,589 2,710 Deferred revenue 2,420 5,494 Lease liabilities 12,742 11,107 Accrued liabilities 2,248 785 Accrued compensation 1,781 1,705 Total deferred tax assets 139,543 127,061 Less valuation allowance – – Total deferred tax assets, net of valuation allowance 139,543 127,061 Deferred tax liabilities: Fixed assets (14,320 ) (1,972 ) ROU assets (11,584 ) (10,007 ) Total deferred tax liabilities (25,904 ) (11,979 ) Net deferred tax assets $ 113,639 $ 115,082 |
Schedule of unrecognized tax positions | Schedule of unrecognized tax positions 2023 2022 Unrecognized tax positions, beginning of year $ 5,133 $ 1,600 Gross (decrease) increase – prior period tax positions (1,693 ) 3,533 Unrecognized tax positions, end of year $ 3,440 $ 5,133 |
Net Income Per Common Share (Ta
Net Income Per Common Share (Tables) | 12 Months Ended |
Apr. 30, 2023 | |
Net income per share attributable to common stockholders: | |
Schedule of earnings per share, basic and diluted | Schedule of earnings per share, basic and diluted Fiscal Year Ended April 30, 2023 2022 2021 Numerator Net income $ 560 $ 127,672 $ 11,212 Series E preferred stock accumulated dividends – – (4,455 ) Impact of Series E preferred stock redemption – – (3,439 ) Net income attributable to common stockholders, basic $ 560 $ 127,672 $ 3,318 Add interest expense on Convertible Notes, net of tax – 1,954 – Net income attributable to common stockholders, diluted $ 560 $ 129,626 $ 3,318 Denominator Weighted average basic common shares outstanding 62,268 61,484 58,222 Effect of dilutive securities: Stock options 1,248 1,830 909 RSUs, PSUs and ESPP 266 384 295 Convertible Notes – 6,776 – Weighted average dilutive common shares outstanding 63,782 70,474 59,426 Net income per share attributable to common stockholders: Basic $ 0.01 $ 2.08 $ 0.06 Diluted $ 0.01 $ 1.84 $ 0.06 |
Schedule of antidilutive shares | Schedule of antidilutive shares Fiscal Year Ended April 30, 2023 2022 2021 Stock options 46 43 829 RSUs, PSUs and ESPP 253 9 – Convertible Notes 6,776 – 928 Series E Preferred Stock – – 1,864 Total 7,075 52 3,621 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details - Cash) - USD ($) $ in Thousands | Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | Apr. 30, 2020 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 38,542 | $ 126,166 | $ 169,915 | |
Restricted cash | 350 | 350 | 350 | |
Total cash, cash equivalents and restricted cash | $ 38,892 | $ 126,516 | $ 170,265 | $ 36,612 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies (Details - Revenue) - USD ($) $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Product Information [Line Items] | |||
Revenues | $ 149,266 | $ 119,597 | $ 95,868 |
Manufacturing Revenue [Member] | |||
Product Information [Line Items] | |||
Revenues | 125,416 | 99,282 | 83,678 |
Process Development Revenue [Member] | |||
Product Information [Line Items] | |||
Revenues | $ 23,850 | $ 20,315 | $ 12,190 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies (Details - Percentage breakdown) - Revenue Benchmark [Member] - Customer Concentration Risk [Member] | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Halozyme Therapeutics [Member] | |||
Product Information [Line Items] | |||
Customer revenue as a percentage of revenue | 53% | 41% | 51% |
I G M Biosciences [Member] | |||
Product Information [Line Items] | |||
Customer revenue as a percentage of revenue | 11% | ||
Gilead Sciences [Member] | |||
Product Information [Line Items] | |||
Customer revenue as a percentage of revenue | 0% | 16% |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies (Details - Useful life) | 12 Months Ended |
Apr. 30, 2023 | |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful lives of property and equipment | Shorter of estimated useful life or lease term |
Other Machinery and Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful lives of property and equipment | 5 – 15 years |
Computer Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful lives of property and equipment | 3 – 5 years |
Furniture and Fixtures [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful lives of property and equipment | 5 – 10 years |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies (Details - Property and Equipment) - USD ($) $ in Thousands | Apr. 30, 2023 | Apr. 30, 2022 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 207,737 | $ 117,412 |
Less: Accumulated depreciation and amortization | (30,368) | (24,457) |
Total property and equipment, net | 177,369 | 92,955 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 97,514 | 37,345 |
Manufactured Product, Other [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 35,501 | 30,089 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 5,028 | 5,326 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 1,681 | 843 |
Construction in Progress [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 68,013 | $ 43,809 |
Summary of Significant Accoun_9
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Product Information [Line Items] | |||
Restricted cash | $ 400,000 | $ 400,000 | |
Revenue recognized for which the contract liability was recorded in the prior year | 40,800,000 | 34,000,000 | |
Change in revenue due to change in estimate | 3,000,000 | 14,700,000 | |
Allowance for doubtful accounts | 500,000 | 18,400,000 | |
Capitalized Interest Costs | 400,000 | 200,000 | |
Depreciation and amortization | 7,200,000 | 4,500,000 | $ 3,500,000 |
Impairment of long-lived assets | 100,000 | ||
Impairment of long-lived assets | 0 | ||
Cash equivalents | 28,700,000 | 116,300,000 | |
Advertising Expense | 700,000 | $ 600,000 | $ 300,000 |
Deferred tax assets | $ 115,000,000 | ||
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member] | UNITED STATES | |||
Product Information [Line Items] | |||
Concentration risk percentage | 100% | 100% |
Debt (Details - Debt component)
Debt (Details - Debt component) - Convertible Debt Carrying Amount [Member] - USD ($) $ in Thousands | Apr. 30, 2023 | Apr. 30, 2022 |
Offsetting Assets [Line Items] | ||
Principal | $ 143,750 | $ 143,750 |
Unamortized issuance costs | (3,127) | (4,173) |
Net carrying amount | $ 140,623 | $ 139,577 |
Debt (Details - Interest expens
Debt (Details - Interest expense) - USD ($) $ in Thousands | 12 Months Ended | |||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | ||
Debt Instrument [Line Items] | ||||
Amortization of debt discount | $ 1,046 | $ 1,030 | $ 916 | |
Convertible Notes [Member] | ||||
Debt Instrument [Line Items] | ||||
Contractual interest expense | 1,395 | 1,603 | 245 | |
Amortization of issuance costs | 1,046 | 1,030 | 54 | |
Amortization of debt discount | [1] | 0 | 0 | 862 |
Total interest expense associated with Convertible Notes | $ 2,441 | $ 2,633 | $ 1,161 | |
[1]As discussed above, the adoption of ASU 2020-06 on May 1, 2021 resulted in the re-combination of the debt and equity components of the Convertible Notes into a single debt instrument. Accordingly, the unamortized debt discount balance and the net carrying amount of the equity component were derecognized. |
Debt (Details Narrative)
Debt (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | |||
Mar. 14, 2023 | Mar. 31, 2021 | Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Debt Instrument [Line Items] | |||||
Proceeds from Convertible Debt | $ 0 | $ 0 | $ 138,464,000 | ||
Payment of capped calls | 0 | 0 | $ 12,837,000 | ||
Revolving Credit Facility [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | |||||
Debt Instrument [Line Items] | |||||
Revolving credit facility, description | (1) a term Secured Overnight Financing Rate (“SOFR”) rate for a specified interest period plus a SOFR adjustment (equal to 0.10%) plus a margin of 1.40% or (2) base rate plus a margin of 0.40% at our option. | ||||
Line of Credit Facility, Commitment Fee Percentage | 0.20% | ||||
Revolving Credit Facility [Member] | Credit Agreement [Member] | |||||
Debt Instrument [Line Items] | |||||
Revolving credit facility, description | (i) $50 million, and (ii) a borrowing base calculated as the sum of (a) 80% of the value of certain of our eligible accounts receivable, plus (b) up to 100% of the value of eligible cash collateral. The Revolving Credit Facility will mature on March 13, 2024 and is secured by substantially all of our assets. | ||||
Outstanding loans | 0 | ||||
Line of credit | $ 15,000,000 | ||||
Convertible Senior Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt face amount | $ 143,800,000 | ||||
Proceeds from Convertible Debt | 138,500,000 | ||||
Debt issuance costs | $ 5,300,000 | ||||
Interest rate | 1.25% | ||||
Maturity date | Mar. 15, 2026 | ||||
Convertible Senior Notes [Member] | Debt Component [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt face amount | $ 99,700,000 | ||||
Debt issuance costs | $ 3,700,000 | ||||
Effective discount rate | 8.78% | ||||
Convertible Senior Notes [Member] | Equity Component [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt face amount | $ 44,100,000 | ||||
Debt issuance costs | $ 1,600,000 | ||||
Convertible Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Fair value of the Convertible Notes | $ 157,300,000 | $ 167,100,000 | |||
Trade price per share | $ 100 | $ 100 |
Leases (Details - Components of
Leases (Details - Components of lease) - USD ($) $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Leases | |||
Operating lease cost | $ 4,386 | $ 3,872 | $ 3,151 |
Variable lease cost | 1,408 | 944 | 676 |
Short-term lease cost | 576 | 515 | 388 |
Finance lease costs: | |||
Amortization of right-of-use assets | 216 | 43 | 82 |
Interest on lease liabilities | 125 | 47 | 4 |
Total lease costs | $ 6,711 | $ 5,421 | $ 4,301 |
Leases (Details - Operating lea
Leases (Details - Operating leases assets and liabilities) - USD ($) $ in Thousands | Apr. 30, 2023 | Apr. 30, 2022 |
Leases | ||
Operating lease right-of-use assets | $ 42,772 | $ 36,806 |
Finance Lease - Property and equipment, net | 2,529 | 2,728 |
Total leased assets | 45,301 | 39,534 |
Current portion of operating lease liabilities | 1,358 | 2,969 |
Finance lease - other current liabilities | 531 | 505 |
Operating lease liabilities, less current portion | 45,690 | 37,886 |
Finance lease liabilities, less current portion | 1,562 | 2,093 |
Total lease liabilities | $ 49,141 | $ 43,453 |
Leases (Details - Operating and
Leases (Details - Operating and finance leases) | Apr. 30, 2023 | Apr. 30, 2022 |
Leases | ||
Weighted average lease term, Operating leases | 16 years 7 months 6 days | 12 years 4 months 24 days |
Weighted average lease term, finance lease | 3 years 8 months 12 days | 4 years 8 months 12 days |
Weighted average discount rate, operating leases | 6% | 3.30% |
Weighted average discount rate, finance lease | 5.30% | 5.30% |
Lease - (Details - Supplemental
Lease - (Details - Supplemental cash flow information) - USD ($) $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Cash paid for amounts included in the measurement of lease liabilities: | |||
Operating cash flows from operating leases | $ 4,069 | $ 2,376 | $ 2,972 |
Operating cash flows from finance leases | 125 | 47 | 5 |
Financing cash flows from finance leases | 505 | 162 | 93 |
Non-cash transactions: | |||
Right-of-use assets obtained upon operating lease modifications and reassessments, net | 9,267 | 4,554 | 0 |
Right-of-use assets obtained in exchange for operating lease obligations | 0 | 16,093 | 0 |
Decapitalization of right-of-use assets upon impairment | 89 | 0 | 0 |
Property and equipment obtained in exchange for finance lease obligation | $ 0 | $ 2,760 | $ 0 |
Leases (Details - Maturities of
Leases (Details - Maturities of Operating Lease Liabilities) $ in Thousands | Apr. 30, 2023 USD ($) |
Statement [Line Items] | |
2024 | $ 4,769 |
2025 | 4,689 |
2026 | 4,796 |
2027 | 4,618 |
2028 | 4,036 |
Thereafter | 56,418 |
Total lease payments | 79,326 |
Less: imputed interest | (30,185) |
Total lease liabilities | 49,141 |
Finance Lease [Member] | |
Statement [Line Items] | |
2024 | 629 |
2025 | 629 |
2026 | 629 |
2027 | 419 |
2028 | 0 |
Thereafter | 0 |
Total lease payments | 2,306 |
Less: imputed interest | (213) |
Total financing lease liabilities | 2,093 |
Operating Lease [Member] | |
Statement [Line Items] | |
2024 | 4,140 |
2025 | 4,060 |
2026 | 4,167 |
2027 | 4,199 |
2028 | 4,036 |
Thereafter | 56,418 |
Total lease payments | 77,020 |
Less: imputed interest | (29,972) |
Total operating lease liabilities | $ 47,048 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) shares in Thousands | Apr. 30, 2023 shares |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Common stock reserved for future issuance | 16,077 |
Conversion Of Convertible Notes [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Common stock reserved for future issuance | 6,776 |
Stock Incentive Plan [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Common stock reserved for future issuance | 8,338 |
Employee Stock Purchase Plan [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Common stock reserved for future issuance | 963 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||||
Apr. 30, 2021 | Jan. 31, 2021 | Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | Apr. 21, 2021 | |
Class of Stock [Line Items] | ||||||
Stock converted, shares issued | ||||||
Dividends paid | $ 4,455,000 | |||||
Proceeds from sale of common stock | $ 0 | $ 0 | 32,141,000 | |||
Payment of stock issuance costs | $ 2,359,000 | |||||
Common Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Stock converted, shares converted | 34,000 | |||||
Stock converted, shares issued | ||||||
Dividends paid | ||||||
Stock issued new, shares | 3,833,000 | |||||
Public offering share price | $ 9 | |||||
Number of shares sold | 500,000 | |||||
Underwritten public offering of common stock | $ 0 | 0 | ||||
Common stock shares issued | 62,691,885 | |||||
Common stock shares outstanding | 62,691,885 | |||||
Series E Preferred Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Stock converted, shares converted | 28,168 | |||||
Conversion price | $ 21 | $ 21 | ||||
Redemption price | $ 25 | $ 25 | ||||
Redemption value | 3,400,000 | |||||
Liquidation preference price per share | 2.625 | |||||
Accrued and unpaid dividends per share | $ 0.08021 | |||||
Dividends paid | $ 0 | $ 0 | $ 4,500,000 | |||
Common Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Stock converted, shares issued | 33,514 | |||||
Common Stock [Member] | Public Offering [Member] | ||||||
Class of Stock [Line Items] | ||||||
Stock issued new, shares | 3,833,335 | |||||
Proceeds from sale of common stock | 34,500,000 | |||||
Payment of stock issuance costs | $ 2,400,000 |
Equity Compensation Plans (Deta
Equity Compensation Plans (Details - Fair value assumptions for options) - Equity Option [Member] | 12 Months Ended | |
Apr. 30, 2023 | Apr. 30, 2022 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Risk-free interest rate | 0.86% | 0.32% |
Expected life (in years) | 4 years 4 months 13 days | 4 years 8 months 8 days |
Expected volatility | 68.64% | 81.42% |
Expected dividend yield | 0% | 0% |
Equity Compensation Plans (De_2
Equity Compensation Plans (Details - Option activity) - Equity Option [Member] $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |
Apr. 30, 2023 USD ($) $ / shares shares | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Number of Options Outstanding, Beginning | shares | 2,505 | |
Weighted Average Exercise Price Outstanding, Beginning | $ / shares | $ 6.88 | |
Number of Options Granted | shares | 0 | |
Weighted Average Exercise Price Granted | $ / shares | $ 0 | |
Number of Options Exercised | shares | (366) | |
Weighted Average Exercise Price Exercised | $ / shares | $ 7.06 | |
Number of Options Cancelled or Expired | shares | (60) | |
Weighted Average Exercise Price Canceled | $ / shares | $ 9.89 | |
Number of Options Outstanding, Ending | shares | 2,079 | |
Weighted Average Exercise Price Outstanding, Ending | $ / shares | $ 6.76 | |
Weighted Average Remaining Contractual Life (in years) Outstanding | 3 years 8 months 8 days | |
Aggregate Intrinsic Value Outstanding | $ | $ 23,654 | [1] |
Exercisable and expected to vest | shares | 2,079 | |
Weighted Average Exercise Price, Exercisable and expected to vest | $ / shares | $ 6.76 | |
Weighted Average Remaining Contractual Life (in years) Vested and expected to vest | 3 years 8 months 8 days | |
Aggregate Intrinsic Value vested and expected to vest | $ | $ 23,654 | [1] |
Exercisable at period end | shares | 1,595 | |
Weighted Average Exercise Price Exercisable, at period end | $ / shares | $ 6.52 | |
Weighted Average Remaining Contractual Life (in years) Exercisable, at period end | 3 years 7 months 2 days | |
Aggregate Intrinsic Value Exercisable at period end | $ | $ 18,447 | [1] |
[1]Aggregate intrinsic value represents the difference between the exercise price of an option and the closing market price of our common stock on April 28, 2023 (the last trading day of fiscal year 2023), which was $18.05 per share. |
Equity Compensation Plans (De_3
Equity Compensation Plans (Details - RSU Activity) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Outstanding, beginning balance | 642 | ||
Weighted average exercise price outstanding, beginning | $ 14.89 | ||
Granted | 780 | ||
Granted, weighted average grant date fair value | $ 17.63 | $ 25.20 | $ 7.29 |
Vested | (366) | ||
Vested, weighted average grant date fair value | $ 15.09 | ||
Forfeited | (50) | ||
Forfeited, weighted average grant date fair value | $ 17.32 | ||
Outstanding, ending balance | 1,006 | 642 | |
Weighted average exercise price outstanding, ending | $ 16.83 | $ 14.89 |
Equity Compensation Plans (De_4
Equity Compensation Plans (Details - PSU Activity) - Performance Stock Units [Member] - $ / shares shares in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Outstanding, beginning balance | 233 | ||
Weighted average exercise price outstanding, beginning | $ 25.31 | ||
Granted | 608 | ||
Granted, weighted average grant date fair value | $ 18.09 | $ 25.36 | $ 0 |
Vested | (161) | ||
Vested, weighted average grant date fair value | $ 20.75 | ||
Forfeited | (158) | ||
Forfeited, weighted average grant date fair value | $ 20.69 | ||
Outstanding, ending balance | 522 | 233 | |
Weighted average exercise price outstanding, ending | $ 19.70 | $ 25.31 |
Equity Compensation Plans (De_5
Equity Compensation Plans (Details - ESPP Fair value assumptions) - Employee Stock Purchase Plan [Member] | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Risk-free interest rate | 3.76% | 0.15% | 0.14% |
Expected life (in years) | 6 months | 6 months | 6 months |
Expected volatility | 68.60% | 59.91% | 75.50% |
Expected dividend yield | 0% | 0% | 0% |
Equity Compensation Plans (De_6
Equity Compensation Plans (Details - Share based compensation) - USD ($) $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Share based compensation | $ 10,978 | $ 7,380 | $ 3,854 |
Cost of Sales [Member] | |||
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Share based compensation | 3,876 | 2,540 | 1,404 |
Selling General And Administrative [Member] | |||
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Share based compensation | $ 7,102 | $ 4,840 | $ 2,450 |
Equity Compensation Plans (De_7
Equity Compensation Plans (Details Narrative) - USD ($) | 12 Months Ended | |||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | Oct. 31, 2022 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Stock reserved for issuance | 16,077,000 | |||
Equity Option [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross | 0 | |||
Proceeds from exercise of stock options | $ 2,600,000 | $ 2,700,000 | $ 3,600,000 | |
Share-Based Payment Arrangement, Option [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Weighted-average grant date fair value of options granted | $ 0 | $ 13.09 | $ 4.74 | |
Aggregate intrinsic value of stock options exercised | $ 3,500,000 | $ 8,100,000 | $ 3,900,000 | |
Unrecognized compensation cost weighted average vesting period | 11 months 26 days | |||
Restricted Stock Units (RSUs) [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Unrecognized compensation cost weighted average vesting period | 2 years 6 months 10 days | |||
Weighted average grant date fair value, other than options | $ 17.63 | $ 25.20 | $ 7.29 | |
Fair value of RSUs vested | $ 6,300,000 | $ 5,500,000 | $ 700,000 | |
Unrecognized compensation cost | $ 15,400,000 | |||
Performance Stock Units [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Unrecognized compensation cost weighted average vesting period | 1 year 4 months 20 days | |||
Weighted average grant date fair value, other than options | $ 18.09 | $ 25.36 | $ 0 | |
Fair value of RSUs vested | $ 3,300,000 | $ 2,100,000 | $ 0 | |
Unrecognized compensation cost | $ 10,300,000 | |||
Employee Stock Purchase Plan [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Weighted average grant date fair value, other than options | $ 4.93 | $ 8.62 | $ 3.17 | |
Stock issued during period, ESPP | 68,646 | 44,364 | 72,409 | |
ESPP weighted average purchase price | $ 12.22 | $ 14.50 | $ 5.84 | |
Plan 2018 [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Stock reserved for issuance | 3,400,000 | |||
Stock Incentive Plans [Member] | Plan 2018 [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Stock reserved for issuance | 8,337,807 | |||
Stock Incentive Plans [Member] | Options And Restricted Stock [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Stock reserved for issuance | 3,926,550 | |||
Stock Incentive Plans [Member] | Future Grants [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Stock reserved for issuance | 4,411,257 |
Income Taxes (Details - Provisi
Income Taxes (Details - Provision for Income taxes) - USD ($) $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Income Tax Disclosure [Abstract] | |||
Federal income taxes at statutory rate | $ 421 | $ 2,659 | $ 2,355 |
State income taxes, net of valuation allowance | 301 | 605 | 0 |
Expiration and adjustments of deferred tax assets | 0 | 0 | 451 |
Change in federal valuation allowance | 0 | (122,703) | 2,450 |
Stock-based compensation including 162M limitations | 615 | (1,153) | (240) |
Research and development credits | 0 | 0 | (4,958) |
Adjustment for federal benefit of state | 0 | 5,326 | 0 |
Permanent differences | 66 | 425 | 4 |
Other, net | 40 | (170) | (62) |
Income tax expense (benefit) | $ 1,443 | $ (115,011) | $ 0 |
Income Taxes (Details - Deferre
Income Taxes (Details - Deferred income taxes) - USD ($) $ in Thousands | Apr. 30, 2023 | Apr. 30, 2022 |
Income Tax Disclosure [Abstract] | ||
Net operating losses | $ 112,194 | $ 99,710 |
Research and development credits | 5,569 | 5,550 |
Stock-based compensation | 2,589 | 2,710 |
Deferred revenue | 2,420 | 5,494 |
Lease liabilities | 12,742 | 11,107 |
Accrued liabilities | 2,248 | 785 |
Accrued compensation | 1,781 | 1,705 |
Total deferred tax assets | 139,543 | 127,061 |
Less valuation allowance | 0 | 0 |
Total deferred tax assets, net of valuation allowance | 139,543 | 127,061 |
Deferred tax liabilities: | ||
Fixed assets | (14,320) | (1,972) |
ROU assets | (11,584) | (10,007) |
Total deferred tax liabilities | (25,904) | (11,979) |
Net deferred tax assets | $ 113,639 | $ 115,082 |
Income Taxes (Details - Unrecog
Income Taxes (Details - Unrecognized tax positions) - USD ($) $ in Thousands | 12 Months Ended | |
Apr. 30, 2023 | Apr. 30, 2022 | |
Income Tax Disclosure [Abstract] | ||
Unrecognized tax positions, beginning of year | $ 5,133 | $ 1,600 |
Gross (decrease) increase – prior period tax positions | (1,693) | 3,533 |
Unrecognized tax positions, end of year | $ 3,440 | $ 5,133 |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Operating Loss Carryforwards [Line Items] | |||
Change in valuation allowance | $ 0 | ||
Comprehensive Income (Loss), Net of Tax, Attributable to Parent | 560,000 | $ 127,672,000 | $ 11,212,000 |
Valuation adjustments | $ 11,300,000 | ||
Domestic Tax Authority [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Net operating loss carry forward | 442,400,000 | ||
Research and development credit carry forwards | 5,800,000 | ||
State and Local Jurisdiction [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Net operating loss carry forward | 294,700,000 | ||
Research and development credit carry forwards | 1,500,000 | ||
Other State [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Net operating loss carry forward | $ 900,000 |
Net Income Per Common Share (De
Net Income Per Common Share (Details - Reconciliation of per share) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Numerator | |||
Net income | $ 560 | $ 127,672 | $ 11,212 |
Series E preferred stock accumulated dividends | 0 | 0 | (4,455) |
Impact of Series E preferred stock redemption | 0 | 0 | (3,439) |
Net income attributable to common stockholders, basic | 560 | 127,672 | 3,318 |
Add interest expense on Convertible Notes, net of tax | 0 | 1,954 | 0 |
Net income attributable to common stockholders, diluted | $ 560 | $ 129,626 | $ 3,318 |
Denominator | |||
Weighted average basic common shares outstanding | 62,268 | 61,484 | 58,222 |
Effect of dilutive securities: | |||
Stock options | 1,248 | 1,830 | 909 |
RSUs, PSUs and ESPP | 266 | 384 | 295 |
Convertible Notes | 0 | 6,776 | 0 |
Weighted average dilutive common shares outstanding | 63,782 | 70,474 | 59,426 |
Net income per share attributable to common stockholders: | |||
Basic | $ 0.01 | $ 2.08 | $ 0.06 |
Diluted | $ 0.01 | $ 1.84 | $ 0.06 |
Net Income Per Common Share (_2
Net Income Per Common Share (Details - Antidilutive shares) - shares shares in Thousands | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Dilutive effect of shares on diluted shares outstanding | 7,075 | 52 | 3,621 |
Equity Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Dilutive effect of shares on diluted shares outstanding | 46 | 43 | 829 |
RSUs, PSUs, and ESPP [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Dilutive effect of shares on diluted shares outstanding | 253 | 9 | 0 |
Convertible Notes [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Dilutive effect of shares on diluted shares outstanding | 6,776 | 0 | 928 |
Series E Preferred Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Dilutive effect of shares on diluted shares outstanding | 0 | 0 | 1,864 |
Employee Benefit Plan (Details
Employee Benefit Plan (Details Narrative) - USD ($) | 12 Months Ended | ||
Apr. 30, 2023 | Apr. 30, 2022 | Apr. 30, 2021 | |
Retirement Benefits [Abstract] | |||
Company matching contributions to 401(k) plan | $ 900,000 | $ 600,000 | $ 500,000 |